These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33708112)

  • 21. Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.
    Abdel-Halim H; Hajar M; Hasouneh L; Abdelmalek SMA
    Drug Des Devel Ther; 2022; 16():2995-3013. PubMed ID: 36110398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue.
    Konrat R; Papp H; Kimpel J; Rössler A; Szijártó V; Nagy G; Madai M; Zeghbib S; Kuczmog A; Lanszki Z; Gesell T; Helyes Z; Kemenesi G; Jakab F; Nagy E
    Front Pharmacol; 2022; 13():861295. PubMed ID: 35846988
    [No Abstract]   [Full Text] [Related]  

  • 23. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
    Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
    ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of new drug indications for COVID-19: A drug repurposing approach.
    Kumari P; Pradhan B; Koromina M; Patrinos GP; Steen KV
    PLoS One; 2022; 17(5):e0267095. PubMed ID: 35609015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators.
    Gorshkov K; Chen CZ; Bostwick R; Rasmussen L; Xu M; Pradhan M; Tran BN; Zhu W; Shamim K; Huang W; Hu X; Shen M; Klumpp-Thomas C; Itkin Z; Shinn P; Simeonov A; Michael S; Hall MD; Lo DC; Zheng W
    bioRxiv; 2020 May; ():. PubMed ID: 32511355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism.
    Yao Y; Zhang Y; Li Z; Chen Z; Wang X; Li Z; Yu L; Cheng X; Li W; Jiang WJ; Wu HJ; Feng Z; Sun J; Fei T
    Biochem Biophys Res Commun; 2023 Oct; 675():113-121. PubMed ID: 37467664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M
    Khan AM; Atia-Tul-Wahab ; Farooq S; Ullah A; Choudhary MI
    Int J Biol Macromol; 2023 Apr; 234():123540. PubMed ID: 36740128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing drugs as COVID-19 therapies: A toxicity evaluation.
    Ngan DK; Xu T; Xia M; Zheng W; Huang R
    Drug Discov Today; 2022 Jul; 27(7):1983-1993. PubMed ID: 35395401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.
    Kouznetsova J; Sun W; Martínez-Romero C; Tawa G; Shinn P; Chen CZ; Schimmer A; Sanderson P; McKew JC; Zheng W; García-Sastre A
    Emerg Microbes Infect; 2014 Dec; 3(12):e84. PubMed ID: 26038505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.
    Andrade BS; Rangel FS; Santos NO; Freitas ADS; Soares WRA; Siqueira S; Barh D; Góes-Neto A; Birbrair A; Azevedo VAC
    Front Pharmacol; 2020; 11():590598. PubMed ID: 33390967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2.
    Hahn F; Häge S; Herrmann A; Wangen C; Kicuntod J; Jungnickl D; Tillmanns J; Müller R; Fraedrich K; Überla K; Kohlhof H; Ensser A; Marschall M
    Pathogens; 2021 Aug; 10(9):. PubMed ID: 34578109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
    Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
    Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.